TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
-3.25%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.29B
AUM Growth
-$158M
(-6.5%)
Cap. Flow
-$50.3M
Cap. Flow
% of AUM
-2.19%
Top 10 Holdings %
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18
Top Buys
| 1 |
Merck
MRK
|
$16.6M |
| 2 |
Illumina
ILMN
|
$13M |
| 3 |
Humana
HUM
|
$9.23M |
| 4 |
Biogen
BIIB
|
$7.74M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$5.28M |
Top Sells
| 1 |
Amgen
AMGN
|
$18.8M |
| 2 |
Abbott
ABT
|
$15.2M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
$15M |
| 4 |
Thermo Fisher Scientific
TMO
|
$13.7M |
| 5 |
Eli Lilly
LLY
|
$10.8M |
Sector Composition
| 1 | Healthcare | 94.94% |
| 2 | Real Estate | 3.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Acadia Pharmaceuticals
ACAD
$4.31B
| $5.76M | 0.25% |
160,147
| – | – |
|
77
Teva Pharmaceuticals
TEVA
$21.3B
| $5.41M | 0.24% |
785,851
| – | – |
|
|
DOC
78
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $5.39M | 0.24% |
303,908
| – | – |
|
79
Labcorp
LH
$22.8B
| $5.28M | 0.23% |
36,578
| – | – |
|
80
Nektar Therapeutics
NKTR
$613M
| $5.17M | 0.23% |
18,912
| – | – |
|
81
Align Technology
ALGN
$9.71B
| $5.12M | 0.22% |
28,278
| – | – |
|
82
PTC Therapeutics
PTCT
$4.42B
| $5.02M | 0.22% |
148,435
+8,827
| +6% | +$299K |
|
83
ResMed
RMD
$39.7B
| $5.01M | 0.22% |
37,110
-15,000
| -29% | -$2.03M |
|
84
Xencor
XNCR
$588M
| $5M | 0.22% |
148,231
+75,849
| +105% | +$2.56M |
|
|
PVLA
85
Palvella Therapeutics, Inc. Common Stock
PVLA
$587M
| $4.94M | 0.22% |
18,116
| – | – |
|
86
Agios Pharmaceuticals
AGIO
$2.04B
| $4.61M | 0.2% |
142,217
-3,125
| -2% | -$101K |
|
|
GBT
87
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.51M | 0.2% |
92,957
+25,441
| +38% | +$1.23M |
|
88
IQVIA
IQV
$31B
| $4.46M | 0.19% |
29,857
+13,466
| +82% | +$2.01M |
|
89
Ligand Pharmaceuticals
LGND
$3.27B
| $4.39M | 0.19% |
70,620
| – | – |
|
|
AMRN
90
Amarin Corp
AMRN
$305M
| $4.38M | 0.19% |
14,428
-13,237
| -48% | -$4.01M |
|
91
United Therapeutics
UTHR
$17.4B
| $4.31M | 0.19% |
54,094
| – | – |
|
92
Acadia Healthcare
ACHC
$2.18B
| $4.23M | 0.18% |
136,200
-36,955
| -21% | -$1.15M |
|
93
Ultragenyx Pharmaceutical
RARE
$3B
| $4.17M | 0.18% |
97,480
+59,000
| +153% | +$2.52M |
|
94
CRISPR Therapeutics
CRSP
$4.73B
| $4.15M | 0.18% |
101,336
-77,012
| -43% | -$3.16M |
|
|
EPZM
95
DELISTED
Epizyme, Inc
EPZM
| $4.12M | 0.18% |
399,604
| – | – |
|
96
Sanofi
SNY
$112B
| $3.98M | 0.17% |
85,941
| – | – |
|
97
Coherus Oncology, Inc. Common Stock
CHRS
$156M
| $3.95M | 0.17% |
195,146
-96,273
| -33% | -$1.95M |
|
98
Masimo
MASI
$7.73B
| $3.93M | 0.17% |
26,436
-1,296
| -5% | -$193K |
|
99
Regenxbio
RGNX
$468M
| $3.89M | 0.17% |
109,248
+96,447
| +753% | +$3.43M |
|
100
argenx
ARGX
$44.9B
| $3.88M | 0.17% |
34,048
+5,667
| +20% | +$646K |
|